A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings.
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed inflation rose by a modest 0.2% in July and 2.7% over the last year. This cooler-than-expected data prompted a significant market rally, with the S&P 500, Dow, and Nasdaq all climbing as investors grew more optimistic. The prevailing view is that easing inflation gives the central bank room to lower interest rates. Lower rates typically reduce borrowing costs for businesses and make stocks more attractive relative to bonds, contributing to widespread gains across sectors like healthcare.
Healthcare services company Sotera Health (NASDAQ:) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 6.4% year on year to $294.3 million. Its non-GAAP profit of $0.20 per share was 15.9% above analysts’ consensus estimates.
Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Danaher (NYSE:DHR) and its peers.
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how research tools & consumables stocks fared in Q1, starting with Sotera Health Company (NASDAQ:SHC).
Healthcare services company Sotera Health (NASDAQ:) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.6% year on year to $254.5 million. Its non-GAAP profit of $0.14 per share was 14.9% above analysts’ consensus estimates.
Shareholders of Sotera Health Company would probably like to forget the past six months even happened. The stock dropped 28.2% and now trades at $11.07. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Let’s dig into the relative performance of Avantor (NYSE:AVTR) and its peers as we unravel the now-completed Q4 research tools & consumables earnings season.
Let’s dig into the relative performance of Bio-Techne (NASDAQ:TECH) and its peers as we unravel the now-completed Q4 research tools & consumables earnings season.
Looking back on research tools & consumables stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Sotera Health Company (NASDAQ:SHC) and its peers.
Healthcare services company Sotera Health (NASDAQ:) met Wall Street’s revenue expectations in Q4 CY2024, but sales fell by 6.5% year on year to $290.2 million. Its non-GAAP profit of $0.21 per share was in line with analysts’ consensus estimates.
